Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease

Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials

(2022) Silvio Danese et al.   LANCET

STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD

(2021) Dan Turner et al.   GASTROENTEROLOGY

Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

(2021) Kristian Reich et al.   LANCET

Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease

(2021) Daniel C. Baumgart et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease

(2020) William J. Sandborn et al.   GASTROENTEROLOGY

JAK–STAT pathway targeting for the treatment of inflammatory bowel disease

(2020) Azucena Salas et al.   Nature Reviews Gastroenterology & Hepatology

The risk of extra-intestinal cancer in inflammatory bowel disease: a systematic review and meta-analysis of population-based cohort studies

(2020) Bobby Lo et al.   Clinical Gastroenterology and Hepatology

Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2

(2020) Philip J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

Pathophysiology of Inflammatory Bowel Diseases

(2020) John T. Chang   NEW ENGLAND JOURNAL OF MEDICINE

Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure‐Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib

(2019) Mohamed‐Eslam F. Mohamed et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Assessment of steroid use as a key performance indicator in inflammatory bowel disease-analysis of data from 2385 UK patients

(2019) Christian P. Selinger et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Exposure–Response Analyses for Upadacitinib Efficacy and Safety in the Crohn's Disease CELEST Study and Bridging to the Extended‐Release Formulation

(2019) Mohamed‐Eslam F. Mohamed et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial

(2019) Désirée van der Heijde et al.   LANCET

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial

(2018) Mark C Genovese et al.   LANCET

The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease

(2015) Marcus Harbord et al.   Journal of Crohns & Colitis

Extraintestinal manifestations and complications in IBD

(2013) Claudia Ott et al.   Nature Reviews Gastroenterology & Hepatology